METROPOLIS
Metropolis Healthcare Limited (METROPOLIS) Stock Analysis
Metropolis Healthcare Limited is a major Indian diagnostic chain offering pathology and wellness testing with strong presence in western and southern India. It serves hospitals, corporates, and walk-in patients with accredited labs. Growth is driven by preventive health and test menu expansion. It is listed on Indian stock exchanges.
Healthcare › Diagnostics & Research
₹593.60
+1.38% 1W | +14.90% 52W
Market Cap
12.3k CR
P/E Ratio
60.9
52W High
₹609
52W Low
₹412.2
Div. Yield
0.33%
Beta
0.2
50 DMA
₹573.7
200 DMA
₹512
Profit Margin
11.8%
Inst. Own.
45.4%
🔥 APPROACHING RESISTANCE
🔥 APPROACHING RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 277 | 308 | 291 | 331 | 313 | 350 | 323 | 345 | 386 | 429 | 406 | 425 | 450 |
| Expenses | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 | 311 | 317 | 339 |
| Operating Profit | 63 | 75 | 65 | 80 | 79 | 90 | 72 | 62 | 90 | 108 | 95 | 108 | 111 |
| OPM % | 23% | 24% | 22% | 24% | 25% | 26% | 22% | 18% | 23% | 25% | 23% | 25% | 25% |
| Other Income | 3 | 1 | 2 | 3 | 2 | 3 | 3 | 7 | 8 | 1 | -0 | 8 | 5 |
| Interest | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 8 | 6 |
| Depreciation | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 | 32 | 39 | 32 |
| Profit before tax | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 | 57 | 70 | 78 |
| Tax % | 26% | 26% | 26% | 28% | 25% | 24% | 26% | 19% | 26% | 26% | 26% | 27% | 27% |
| Net Profit | 29 | 36 | 27 | 37 | 38 | 47 | 31 | 29 | 45 | 53 | 42 | 51 | 57 |
| EPS in Rs | 1.41 | 1.73 | 1.33 | 1.78 | 1.85 | 2.27 | 1.53 | 1.41 | 2.17 | 2.54 | 2.00 | 2.46 | 2.73 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 456 | 475 | 545 | 647 | 761 | 856 | 998 | 1,228 | 1,148 | 1,208 | 1,331 | 1,646 | 1,710 |
| Expenses | 339 | 359 | 405 | 467 | 559 | 619 | 708 | 880 | 855 | 920 | 1,023 | 1,240 | 1,288 |
| Operating Profit | 117 | 116 | 140 | 181 | 203 | 237 | 290 | 348 | 293 | 288 | 308 | 406 | 422 |
| OPM % | 26% | 24% | 26% | 28% | 27% | 28% | 29% | 28% | 26% | 24% | 23% | 25% | 25% |
| Other Income | 7 | 29 | 39 | 6 | 8 | -17 | 12 | 34 | 15 | 9 | 15 | 16 | 14 |
| Interest | 2 | 2 | 2 | 4 | 4 | 13 | 12 | 25 | 32 | 28 | 24 | 29 | 26 |
| Depreciation | 21 | 17 | 17 | 19 | 20 | 39 | 46 | 63 | 89 | 94 | 109 | 134 | 135 |
| Profit before tax | 101 | 128 | 160 | 164 | 187 | 169 | 244 | 293 | 188 | 175 | 191 | 259 | 276 |
| Tax % | 33% | 36% | 33% | 32% | 34% | 24% | 25% | 27% | 24% | 26% | 24% | 26% | |
| Net Profit | 68 | 82 | 107 | 112 | 124 | 128 | 183 | 215 | 143 | 128 | 146 | 191 | 203 |
| EPS in Rs | 15.44 | 20.10 | 26.61 | 27.29 | 5.99 | 6.29 | 8.95 | 10.46 | 6.98 | 6.24 | 7.00 | 9.17 | 9.73 |
| Dividend Payout % | 0% | 100% | 49% | 0% | 55% | 32% | 22% | 19% | 29% | 16% | 0% | 55% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 13.0% | 11.0% | 13.0% |
| Profit CAGR | 11.0% | 1.0% | 11.0% |
Shareholding Pattern
Promoters48.89%
FIIs12.83%
DIIs32.40%
Public5.87%
Promoters48.89%
FIIs12.52%
DIIs33.10%
Public5.48%
Promoters48.87%
FIIs11.68%
DIIs34.73%
Public4.69%
Promoters48.86%
FIIs10.43%
DIIs35.80%
Public4.92%
Promoters48.86%
FIIs11.03%
DIIs35.12%
Public5.00%
Promoters49.75%
FIIs25.67%
DIIs13.64%
Public10.94%
Promoters49.67%
FIIs18.90%
DIIs24.86%
Public6.57%
Promoters48.89%
FIIs15.29%
DIIs30.30%
Public5.51%
Promoters48.86%
FIIs10.43%
DIIs35.80%
Public4.92%
Promoters48.86%
FIIs11.03%
DIIs35.12%
Public5.00%
METROPOLIS
Holdings Analysis
Key strengths & risk signals
67
Overall
64
Fundamental
71
Technical
Risks (1)
OVERVALUED! PEG of 57.60 means expensive relative to growth rate.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (555.1) is above 200-day average (498.8) - positive signal.
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
STRONG POSITION! Current price (563.2) is above both moving averages.
Fundamental & Technical Analysis
67Overall
64Fundamental
71Technical
Fundamental Breakdown
Growth Quality
16/30
Revenue CAGR: 11.0% (GOOD, 11/15). Profit CAGR: 1.0% (SLOW, 5/15).
Profit Margin
5/10
DECENT EFFICIENCY! 11.5% profit margin - acceptable profitability.
PEG Valuation
0/10
OVERVALUED! PEG of 57.60 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.34% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.15 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 9.69% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (555.1) is above 200-day average (498.8) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (563.2) is above both moving averages.
Trend Pattern
10/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
6/10
POSITIVE YEAR! Stock gained 13.2% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 333,784 vs down days: 284,812. Ratio: 1.17x
RSI
3/5
NEUTRAL! RSI at 47.7 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 76.7% of 52W range - positive territory.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - -3.3% (1 week), 2.5% (1 month), 2.5% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
METROPOLIS
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-09-02 | Concall PDF | |
| Q4FY262026-05-19 | Concall PDF | |
| Q3FY262026-02-11 | Concall PDF | |
| Q2FY262025-11-11 | Concall PDF |
Peer Comparison
Healthcare · Diagnostics & Research · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| METROPOLIS | ₹593.60 | 60.9 | 11.8% | 12.8% | 10.0% | +14.9% | 67 | APPROACHING RESISTANCE | +25.7% | +11.4% | +16.6% | +6.0% |
| SYNGENE | ₹385.10 | 70 | 6.1% | 5.4% | -12.0% | -43.7% | 54 | BOUNCE FROM SUPPORT | -110.4% | -106.1% | -15.8% | -29.0% |
| THYROCARE | ₹571.50 | 51.7 | 20.1% | 16.7% | 36.2% | +36.8% | 87 | BREAKDOWN | +34.2% | +10.8% | +24.4% | +7.1% |
| VIJAYA | ₹1,556.10 | 85.3 | 21.9% | 21.0% | 26.9% | +48.5% | 82 | APPROACHING RESISTANCE | +37.6% | +10.9% | +22.8% | +5.3% |
| VIMTALABS | ₹616.00 | 34.5 | 18.9% | 8.9% | 17.2% | -21.1% | 67 | BREAKDOWN | +11.1% | -0.5% | +11.8% | -0.1% |
| KRSNAA | ₹554.60 | 18.7 | 11.6% | 16.6% | 17.8% | -37.0% | 65 | BREAKDOWN | -19.0% | -60.2% | +22.0% | +22.3% |
| SURAKSHA | ₹348.50 | 50.7 | 11.0% | 17.7% | 70.3% | +4.6% | 82 | BREAKDOWN | +38.3% | +106.3% | +20.7% | +7.6% |
| LALPATHLAB | ₹1,924.60 | 59.3 | 18.7% | 11.1% | 28.3% | +12.0% | 87 | BREAKDOWN | +28.0% | +29.1% | +19.1% | +13.5% |
Data from TradeAlone · Updated daily
METROPOLIS News
Metropolis Healthcare Limited (metropolis) Announces Investor & Analyst Meet 2026: Strengthen the Core. Expand Adjacencies. Compound Shareholder Value.2026-08-27Metropolis Healthcare Limited (metropolis) Q1fy27: Revenue Up 17%, Ebitda Surges 27% Yoy2026-08-04Metropolis Healthcare Limited (METROPOLIS) gains 5% intraday, clears resistance at ₹5502026-07-20Metropolis Healthcare Limited (METROPOLIS) gives up ground after breakout, falls 6% intraday2026-07-17Metropolis Healthcare Limited (METROPOLIS) bounces back 5% intraday2026-06-16Metropolis Healthcare Limited (METROPOLIS) bounces back 5% intraday2026-06-16Metropolis Healthcare Limited Q4 & FY26: Revenue Up 32%, PAT Surges 23%2026-05-13
